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Abstract
Proteolysis is an irreversible post-translational modification that regulates protein function and signal transduction. This in-
cludes remodelling of the extracellular matrix, release of membrane-bound cytokines and receptor ectodomains, as well as the 
initiation of intracellular signalling cues. Members of the adamalysin protease subfamily, in particular the ADAM (a disintegrin 
and metalloprotease) and ADAMTS (the ADAM containing thrombospondin motif) families, are involved in these processes. 
This review presents an overview of how ADAM and ADAMTS proteins are involved in liver physiology and pathophysiology.
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Introduction
The liver harbours different cell types, including hepatocytes, 
cholangiocytes, resident macrophages called Kupffer cells 
(KCs), sinusoidal endothelial cells (SECs) and hepatic stellate 
cells (HSCs). Hepatocytes, the liver parenchymal cells, make 
up the vast majority of cells and fulfil multiple vital body 
functions such as protein synthesis and storage; detoxification; 
synthesis of cholesterol, phospholipids and bile salts; and se-
cretion of bile. Bile is then stored in the gallbladder and drained 
through bile ducts formed by cholangiocytes to aid in the di-
gestion and absorption of dietary fats and fat-soluble vitamins 
in the duodenum. The liver sinusoids are lined with KCs and 
SECs, while HSCs represent perisinusoidal cells found in the 
space of Disse, an area between liver SECs and hepatocytes. 
In homeostatic conditions, HSCs store fat and fat-soluble vita-
mins in the liver, in particular vitamin A (retinol, retinoic acid).
Upon acute liver damage, hepatocytes restore the lost liver 
mass by proliferation and hypertrophy (1). However, under 
chronic toxic, viral or carcinogenic insult, the proliferation 
of hepatocytes is inhibited, and they often become senescent. 
Under these circumstances, hepatic progenitor cells (HPCs) are 
activated and observed to proliferate in a variety of chronic liver 
diseases, including alcoholic liver disease, non-alcoholic fatty 
liver disease, steatohepatitis and in the iron overload disorder, 
haemochromatosis. HPCs are small, stem-cell-like cells with 
unclear origin and have the capacity to differentiate into hepa-
tocytes or cholangiocytes, depending on the underlying injury 
stimulus (2). Damage signals from cellular compartments lead 
to the transdifferentiation of HSCs to proliferative and fibro-
genic myofibroblasts. These “activated” HSCs respond by de-
positing collagen, resulting in the formation of scar tissue, which 
may progress to liver cirrhosis in severe cases. Numerous studies 
have reported a close temporal and spatial organisation of KCs, 
HPCs and HSCs, which display an intimate interplay and or-
chestrate liver regeneration versus disease progression through 
cytokine and chemokine cross-talk (2–6). These complex signal-
ling networks require precise regulations not only at the cellular 
level but also at the molecular level. Members of the metzincin 
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protease family have been shown to be involved in different as-
pects of chronic liver disease and tumour formation.
The Metzincin Superfamily
The superfamily of zinc proteases or metzincins is charac-
terised by the presence of a protease domain containing an 
invariant HExxHxxGxxH zinc-binding motif  (7, 8). It is sub-
divided into four subfamilies: matrixins, adamalysins, astacins 
and bacterial serralysins. The SVMPs (snake venom metallo-
proteinases), the ADAMS (a disintegrin and metalloprotein-
ases) and ADAMTs (ADAMs containing thrombospondin 
motifs) form the adamalysin subfamily (9). The catalytic do-
mains of metzincins share a similar overall structure with the 
catalytic cleft positioned between an N-terminal subdomain 
(NSD) and a C-terminal subdomain (CSD) (8). The NSD is 
anchored by a five-stranded β sheet, followed by a central α 
helix which contains the HExxH motif supplying two of the 
histidines involved in Zn2+-coordination and the glutamate 
residue that participates in catalysis (Figure  1). C-terminal 
to the α-helix, a conserved methionine turn is packed against 
the zinc-binding site (8, 10). Both ADAM and ADAMTS 
protein structures are thought to exist as “open” or “closed” 
structures representing another layer of regulation. Cur-
rently, this has been shown for the members ADAM17 and 
ADAMTS4 and 5, respectively (11, 12). In the case of the 
closed ADAMTS4 conformation, movement of the S2’ loop 
towards the catalytic centre precludes substrate binding and 
leads to the release of an additional Ca2+ ion (11).
The ADAM Family
In mammals, ADAMs are expressed in a wide range of tis-
sues. Given their numerous substrates, they have diverse 
functions in development, physiology and pathology (9). 
The human genome encodes for 22 functional ADAM pro-
teins, of which 10 are considered proteolytically inactive (13). 
ADAMs without protease activity are thought to facilitate 
protein folding and protein–protein interactions.
The domain structure of ADAM proteases comprises 
an N-terminal inhibitory pro-domain, a catalytic metallo-
protease domain, a disintegrin domain with a cysteine-rich 
region, an epidermal growth factor (EGF)-like domain, a 
transmembrane domain and a cytoplasmic tail (Figure 1a). 
ADAM proteases are synthesised as catalytically inactive 
transmembrane proteins of about 750 amino-acid length 
into the endoplasmic reticulum. The N-terminal pro-domain 
is thought to have chaperone and inhibitory functions as it 
interferes with the Zn2+-ion in the catalytic centre. Within the 
Golgi apparatus, ADAMs undergo further complex glycosy-
lation and are subjected to proteolytic cleavage by the Furin 
protease, thereby liberating the N-terminal pro-domain. 
However, for ADAM8 and ADAM28, autocatalytic pro-do-
main cleavage was demonstrated (14, 15). Recently it has been 
shown that the recombinant pro-domain of ADAM17 can be 
harnessed as a specific inhibitor in vitro and in vivo (16).
The catalytic domain is conserved among the ADAM 
family members and contains the zinc-binding motif  (HEx-
GHxxGxxHD) (Figure 1 a and b) (17). The adjacent disinte-
grin and cysteine-rich domains are suggested to be involved 
in autoregulation as they fold back and limit access to the 
catalytic site in the unliganded state (10, 18). The disintegrin 
domain may also participate in cell–cell adhesion processes 
and has been shown for ADAM10 to play a role in substrate 
recognition in concert with the cysteine-rich domain (9, 19). 
The cytoplasmic tails of transmembrane ADAMs contain 
phosphorylation sites for several kinases, denoting a role in 
regulation of protease activity and downstream signalling 
(9). ADAM-mediated shedding can either be constitutive or 
activated by G-protein-coupled receptors; Ser/Thr-kinase ac-
tivity, including protein kinase C (PKC), ERK and p38; and 
increased intracellular Ca2+(9, 20, 21).
ADAM proteases play a major role in proteolytic ec-
todomain cleavage, a process termed “shedding” (Figure 2). 
Functionally diverse proteins have been shown to be sub-
jected to ectodomain shedding with differential physiolog-
ical consequences. Shedding of receptor molecules such as 
transforming growth factor (TGF) β receptor abrogates its 
signalling. Importantly, the soluble ectodomain has the ca-
pacity to work as a scavenger and binds the corresponding 
cytokine (22). The receptor for interleukin 6 (IL-6) is an ex-
ception because the IL-6/soluble IL-6R (sIL-6R) complex 
Figure 1. General structure of ADAM and ADAMTS pro-
teases. (a) General domain structure of ADAM proteases. 
(b) X-ray structure (6BE6.pdb) of ADAM10, including cat-
alytic, disintegrin and cysteine-rich domains. The catalytic 
zinc is highlighted in grey and the zinc-binding motif  in pale 
green. (c) General domain structure of ADAMTS proteases. 
(d) X-ray structure of ADAMTS1 (2V4B.pdb), including 
catalytic and disintegrin domain. The catalytic zinc is high-
lighted in grey and the zinc-binding motif  in pale green.
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Figure 2. Signal activities of ADAM and ADAMTS proteinases in the liver. (a) ADAM protease activity, ADAM17 in particu-
lar, can be regulated by protein phosphorylation. Active ADAM proteases are involved in the release of receptor ectodomains, 
thereby blunting receptor signalling in most of the cases, the release of membrane-bound cytokines and the initiation of intracel-
lular signalling by regulated intramembrane proteolysis (RIP). (b) Selected proteolytic events of the indicated ADAM proteinases 
in different cell types of the liver. (c) Selected proteolytic and non-proteolytic events of the indicated ADAMTS proteinases in 
different hepatic cell types. BEC, biliary epithelial cells; EC, endothelial cell; gp130, glycoprotein 130; HSC, hepatic stellate cells; 
HC, hepatocyte; ICD, intracellular domain; IL-6R, interleukin 6 receptor; KC, Kupffer cell; LAP-TGFβ, latency-associated 
peptide-transforming growth factor β; MICA, MHC class I polypeptide-related sequence A; sIL-6R, soluble IL-6R; vWF – von 
Willebrand factor. 
induces signalling via gp130 on target cells. This process has 
been termed “IL-6 trans-signalling.” (23, 24)
Membrane-bound cytokines and growth factors are 
also liberated from the membrane by ectodomain shed-
ding ( Figure 2). The most prominent example is the fam-
ily of  EGF ligands, comprising heparin-binding EGF 
(HB-EGF), TGFα, epiregulin and neuregulin, which are 
shed by ADAM17, and known to play key roles in tumour 
growth (25). The most prominent substrate of  ADAM10 is 
the Notch receptor, which has been implicated in develop-
mental processes, stem cell growth and differentiation (26). 
In addition, there is evidence that ADAMs are able to de-
grade extracellular matrix (ECM) components: ADAM10 
cleaves type IV collagen; ADAM13 and ADAM9 degrade 
fibronectin (27).
ADAM9
ADAM9 processes a wide range of substrate molecules, in-
cluding amyloid precursor protein (APP), collagen XVII and 
HB-EGF, and has been linked to cell proliferation, adhesion 
and migration (28).
Transcriptomic analysis of  fibrotic liver tissue revealed 
that expression of  ADAM9 correlated with the activation 
of  HSCs, as assessed by quantitation of  alpha-smooth 
muscle actin (αSMA), independent of  the underlying dis-
ease aetiology. Northern blots analysis demonstrated that 
ADAM9 expression was localised to HSCs (Figure 2b) 
and that expression of  ADAM9 significantly increased 
in activated compared to quiescent HSCs (Table 1) (29). 
These data suggest that ADAM9 is important for ECM 
remodelling during hepatic fibrosis progression and may 
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Table 1. Overview of known ADAM and ADAMTS proteinase activities in the liver and their association with hepatic 
diseases.
The ADAM family
Family member Associated disease Substrate(s) Cell type Reference
ADAM9 Fibrotic liver disease ECM components Activated HSCs (29, 30)
HCC MIC-A Hepatocytes (32)









ADAM10 Liver homeostasis pot. indep. of catalytic activity Hepatocytes, HPCs (37)
Liver fibrosis CX3CL1 Activated HSCs (38, 39)
Murine cholestasis c-Met Hepatocytes (41)
HCC MIC-A Hepatocytes (39)
Liver metastasis L1CAM Tumour cells (43)
c-Met HSCs (44, 45)
ADAM12 Cirrhotic liver pot. ECM remodelling Activated HSCs (47)
HCC pot. ECM remodelling Activated HSCs (48)
ADAM17 Liver damage CX3CL1 Activated HSCs (38)
HCC Notch Activated HSCs (53)
pot. EGFR ligands Hepatocytes (50, 51)
pot. IL-6R Kupffer cells (56)
The ADAMTS family
Family member Associated disease Substrate(s) Cell type Reference
ADAMTS1 Fibrotic liver disease Binding to LAP-TGFβ HSCs (59)
ADAMTS2 Murine liver fibrosis Pro-collagen HSCs (62)
ADAMTS13 SAH vWF endothelium (71)
ALI, ALF (72)
Fibrotic liver disease (74–78)
ADAM, a disintegrin and metalloprotease; ADAMTS; the ADAMs containing thrombospondin motif; ECM, extracellular 
matrix; HCC, hepatocellular carcinoma; MIC-A, major histocompatibility class I-related chain A; HSC, hepatic stellate cell; 
HPC, hepatic progenitor cell; L1CAM, L1 cell adhesion molecule; IL-6R, interleukin 6 receptor; EGFR, epidermal growth 
factor receptor; LAP-TGFβ, latency-associated peptide-transforming growth factor β; SAH, severe alcoholic hepatitis; ALI, 
acute liver injury; ALF, acute liver failure; vWF, von Willebrand Factor.
thereby contribute to the establishment of  an environment 
conducive to hepatocellular carcinoma (HCC). Indeed, 
various studies have reported ADAM9 overexpression in 
HCC (30–32), and high expression levels of  ADAM9 have 
been linked to tumour aggressiveness (30). Beside its ef-
fect on HSCs, ADAM9 was found to promote ectodomain 
shedding of  major histocompatibility class I-related chain 
A (Figure 2b). Consequently, HCC cells with siRNA-
mediated suppression of  ADAM9 were more suscepti-
ble to natural killer cell-mediated cytolysis. Interestingly, 
sorafenib-treatment reduced ADAM9 expression, and 
enhanced major histocompatibility class I-related chain 
A protein levels and anti-tumour response of  natural 
killer cells (32). An alternatively spliced ADAM9 variant 
(ADAM9-S), secreted by activated HSCs and stromal liver 
myofibroblasts, has been shown to promote tumour metas-
tasis to the liver (Table 1). Through its disintegrin domain, 








 integrins on 
colon carcinoma cells and is able to cleave laminin, thereby 
promoting tumour cell invasion (33).
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ADAM10
In most tissues investigated, ADAM10 is the major protease 
that initiates Notch signalling. In the liver, biliary tree forma-
tion (34, 35) and differentiation of HPCs into cholangiocytes 
(4) are dependent on Notch signalling (Figure 2a). This is also 
reflected by the finding that patients with Alagille syndrome 
who suffer from biliary paucity and subsequent cholestasis 
display mutations in the Notch ligand Jagged-1 (36). We re-
cently investigated the role of ADAM10 under physiological 
conditions by generating liver-specific ADAM10-deficient 
mice. Surprisingly, we observed that ADAM10 was dispens-
able for Notch2 activation in vitro in an HPC line, and for bil-
iary tree formation in vivo (37), further suggesting that during 
development, Notch signalling in hepatoblasts does not rely 
on ADAM10. However, we observed that hepatic loss of 
ADAM10 leads to the down-regulation of biliary transport-
ers, resulting in spontaneous hepatocyte necrosis (Table 1). 
Furthermore, loss of ADAM10 resulted in an accumulation 
of HPCs that might at least, in part, be the consequence of 
enhanced signalling through the hepatocyte growth factor re-
ceptor c-Met (37).
Overexpression of ADAM10 has been reported in chronic 
liver disease associated with liver fibrosis (38) and in HCC 
(39, 40) (Table 1). In HSCs, ADAM10 is involved in the re-
lease of the soluble chemokine, CX3CL1, thereby facilitating 
recruitment of inflammatory cells (38). Furthermore, c-Met 
ectodomain release by ADAM10 from HSCs correlated with 
hepatic injury in the murine 3,5-diethoxycarbonyl-1,4-dihy-
drocollidine (DDC) cholestasis model (41). Soluble c-Met 
has previously been identified as a decoy receptor and might 
therefore restrict the proliferative response after liver dam-
age (42). SiRNA-mediated suppression of ADAM10 in 
the human liver cancer cell line, HepG2, decreased cellular 
proliferation, the ability to grow in semi-solid medium and 
its tumorigenic potential in xenografts (39, 40). ADAM10 
might also be involved in anti-tumour immunity as it has 
been demonstrated that major histocompatibility class I-re-
lated chain A is a substrate for ADAM10 in HepG2 cells 
( Figure  2b, Table  1), where its surface localisation was en-
hanced in the absence of ADAM10 (39). Inhibition of 
ADAM10 might therefore represent an attractive avenue to 
increase the anti-tumour immune response.
In addition to its role in fibrotic liver disease and HCC, 
ADAM10 seems to have a role in the establishment of liver 
metastasis. The neuronal cell adhesion receptor L1-CAM, 
which is expressed on colon cancer cells, is proteolytically 
processed by ADAM10, generating a L1-CAM intracellu-
lar domain (ICD). An increased L1-CAM ICD formation 
through enhanced ADAM10 activity resulted in enhanced 
liver metastasis (Table 1) (43). Furthermore, tumour cell-se-
creted tissue inhibitor of metalloproteinase (TIMP) 1 was 
shown to inhibit ADAM10-mediated c-Met processing 
(Figure 2b) and thereby c-Met signalling in liver metastasis. 
Suppression of TIMP-1 lowered the metastatic potential of 
tumour cells, while circulating TIMP-1 levels correlated with 
an increased risk for liver metastasis formation (44, 45). Very 
recently, the same group demonstrated that TIMP-1 secreted 
from pancreatic premalignant lesions activates HSCs in the 
liver via binding to the tetraspanin CD63, thereby preparing 
a hepatic premetastatic niche (46).
ADAM12
Due to alternative splicing, ADAM12 can be expressed as a long 
(ADAM12L) or as a short (ADAM12S) form. The latter is solu-
ble due to its lack of transmembrane and cytoplasmic domains 
(47). Both ADAM12 isoforms were found to be up-regulated 
upon TGFβ stimulation in activated HSCs but not in hepatoc-
ytes. Furthermore, expression of ADAM12 was increased in cir-
rhotic livers and liver cancer and localised to cells of the tumour 
stroma, presumably HSCs (Table 1) (30, 48). ADAM12 was also 
detectable in circulation and correlated with overall survival 
(48). Interestingly, in another study, overall patient survival and 
ADAM12 expression correlated with the expression of the Te-
traspanin Tspan8 (49), which is often up-regulated in HCC (50). 
Down-regulation of Tspan8 in HCC lines reduced ADAM12L 
expression and tumourigenicity in a mouse xenograft model 
(49). However, more in-depth analysis is needed to identify def-
inite substrates of ADAM12 and decipher its potential role in 
tumour stroma dynamics and ECM remodelling.
ADAM17
Reports using in vitro experiments demonstrated that ADAM17 
mediates the release of EGFR ligands in hepatocytes upon ex-
posure to tumour necrosis factor (TNF) α (51) or TGFβ (52), 
suggesting that ADAM17 on hepatocytes might be involved in 
liver regeneration (Table 1). Furthermore, release of CX3CL1 
from HSCs was also shown to be mediated by ADAM17, cor-
relating with enhanced inflammatory cell infiltration upon liver 
damage (38). However, a clear in vivo evidence for a role of 
ADAM17 in liver regeneration is still lacking.
Overexpression of  ADAM17 has been reported in human 
HCC and diethylnitrosamine (DEN)-induced murine HCC 
model (53). In tumour cells, ADAM17 is essential for Notch 
signalling (Figure 2b), resulting in the maintenance of  a 
cancer stem cell phenotype (54) with enhanced migratory 
abilities through activation of  integrin β1 (53, 55). Inter-
estingly, it was shown that formation of  hepatic metastases 
is enhanced by the release of  soluble Notch ligands from 
endothelial cells, which in turn activates Notch on colorec-
tal cancer cells. In vitro experiments using small molecule 
inhibitors suggested that proteolytic release of  Notch lig-
ands might be mediated by ADAM17 (56). However, the 
question whether ADAM17 is also important for Notch 
signalling under physiological conditions, in particular in 
the liver, remains unanswered.
ADAM17 is a major protease for the membrane-bound 
IL-6R, leading to the release of soluble IL-6R (Figure 2b). 
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In contrast to many other soluble receptors, sIL-6R is able to 
bind IL-6 and induce signalling through the signal-transduc-
ing subunit, gp130 (24). This process is called IL-6 trans-sig-
nalling. We recently demonstrated that IL-6 trans-signalling 
is critically involved in HCC tumour initiation and tumour 
angiogenesis (56). Taken together, liver tumourigenesis ap-
pears to depend on ADAM17 proteolysis. However, more de-
tailed in vivo analyses are needed to clarify if  ADAM17 can 
be harnessed as a potential target in HCC therapy.
The ADAMTS Family
Unlike ADAM family proteins, members of the ADAMTS 
protease family contain neither transmembrane nor cytoplas-
mic domains and are synthesised as extracellular proteins. 
Instead, all family members contain at least one thrombo-
spondin (TSP) type-1 repeat (TSR) that comprises approxi-
mately 50 amino-acids and is similar to the type-1 repeats in 
TSP-1 and TSP-2 (57). The human ADAMTS family con-
tains 19 members that can be clustered into eight different 
evolutionary clades, depending on their domain organisa-
tion and known functions. The aggrecanase and proteogly-
canase clades contain members (ADAMTS1, 4, 5, 8, 15, 9, 
20) that are involved in the processing of hyaluronan-bind-
ing chondroitin sulphate proteoglycan extracellular proteins, 
including versican and aggrecan. Another clade encloses 
pro-collagen N-propeptidases (ADAMTS2, 3, 14) that con-
fer maturation of triple helical collagen fibrils (57).
The overall domain organisation of ADAMTS proteins can 
be structured into a metalloproteinase domain and an ancillary 
domain (Figure 1c). The metalloproteinase domain consists 
of a pro-domain, the catalytic metalloprotease domain and a 
disintegrin-like module. The catalytic domain of ADAMTS 
members contain a HExxHxBG(N/S)BxHD consensus motif, 
with B as a large non-polar residue and three histidines that 
coordinate the Zn2+ metal ion (Figure 1c and d) (8, 57, 58). 
To date, no ADAMTS protein has been identified to associ-
ate with integrins. In contrast, crystal structure data suggest 
that the disintegrin-like domain is an integral part of the cata-
lytic core of ADAMTS proteins (11, 59). The composition of 
the ancillary domain varies between the different ADAMTS 
members; however, all have at least one TSR motif in common 
(Figure 1c). ADAMTS proteins display multiple functions 
during tissue development and homeostasis, and their dysreg-
ulation has been associated with various diseases. During de-
velopment, members of the aggrecanase and proteoglycanase 
clade process the ECM component versican ensuring enough 
structural support on the one hand, while allowing dynamic 
remodelling on the other hand (57).
ADAMTS1 and ADAMTS2
The aggrecanase/proteoglycanase group member ADAMTS1 
is involved in the processing of ECM components (60). 
Expression of ADAMTS1 positively correlated with progres-
sion of hepatic fibrosis to cirrhosis. ADAMTS1 was localised 
to HSCs. Interestingly, ADAMTS1 expression is elevated 
in activated HSCs and is associated with latency-associated 
peptide (LAP)-TGFβ, resulting in TGFβ activation (Figure 
2c, Table 1). Consequently, a KTFR sequence-containing 
peptide derived from ADAMTS1 was sufficient to reduce col-
lagen deposition in the murine carbon tetrachloride cirrhosis 
model (61). ADAMTS2 cleaves the pro-peptides of type I 
and type II pro-collagens prior to fibril formation. Its promi-
nent role in collagen maturation has been further emphasised 
by the discovery of ADAMTS2 mutations in Ehlers-Danlos 
syndrome type VIIC (62), which is characterised by extreme 
skin fragility and joint laxity, among other symptoms. The 
impact of ADAMTS2 on liver biology has been previously 
shown in experimental liver disease using carbon tetrachlo-
ride (Table 1). While the initial parenchymal damage was 
similar, HSC activation and collagen deposition were signifi-
cantly reduced in ADAMTS2-/- mice compared to appropri-
ate controls (Figure 2c, Table 1) (63).
ADAMTS13
ADAMTS13 is the sole member of the von Willebrand Fac-
tor (vWF)-cleaving protease (vWFCP) clade. The vWF is a 
pro-thrombogenic glycoprotein, produced constitutively as 
ultra-large, multimeric protein by endothelial cells (64). After 
endothelial injury, vWF binds on one side to sub-endothe-
lial collagen and on the other side to platelet glycoproteins, 
gpIb/IX/V, leading to platelet tethering at the injury site. 
Under fluid shear stress, vWF gets proteolytically processed. 
Thus, ADAMTS13 generates smaller, non-functional vWF 
fragments (Figure 2c) (65). Loss of ADAMTS13 catalytic 
activity, either by recessive mutations (66) or by inhibitory 
auto-antibodies (67), leads to the accumulation of ultra-large 
vWF and the formation of platelet-rich microthrombi in the 
micro-vasculature causing a life-threatening rare disorder 
called thrombotic thrombocytopenia purpura (68, 69). Low 
levels of ADAMTS13 are also found in patients with sep-
sis-induced disseminated intravascular coagulation and are 
associated with increased mortality (70).
ADAMTS13 expression is predominantly found in the liver 
but also to some extent in skeletal muscles, placenta and the 
lung (71). It is therefore not surprising that patients with se-
vere alcoholic hepatitis (SAH) display reduced plasma activ-
ity of ADAMTS13 and reduced vWF proteolysis (Table 1). 
In SAH patients with multiorgan failure, ADAMTS13 levels 
were markedly reduced, resulting in increased platelet clump-
ing and subsequent multiorgan failure (72). Similarly, pa-
tients with acute liver injury and acute liver failure displayed 
an imbalance between vWF and ADAMTS13 (Table 1), and 
low ADAMTS13 levels were associated with higher grades of 
encephalopathy and lower survival rates potentially linked to 
microthrombus formation (73).
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A more detailed analysis localised ADAMTS13 expres-
sion to αSMA-positive HSCs in a patient with hepatitis 
C-related chronic hepatitis, suggesting a role in fibrotic liver 
disease (74). Accordingly, ADAMTS13 expression levels 
were increased not only in activated rat HSCs in vitro but 
also in HSCs in vivo in carbon tetrachloride-injured rats 
(75). Patients with liver cirrhosis displayed increasing levels 
of vWF with increasing severity according to Child-Pugh 
classification, while collagen-binding activity of vWF was 
decreased in these patients, partially correlating with in-
creased ADAMTS13 activity (76). However, two other stud-
ies detected decreased ADAMTS13 levels in cirrhotic livers, 
linking ADAMTS13 levels to an increased platelet thrombi 
formation (77, 78). A very recent study demonstrated that 
while ADAMTS13 did not correlate with the Child-Pugh 
score in cirrhotic patients, low levels of ADAMTS13 were 
associated with portal vein thrombosis (79). In contrast, in 
patients with non-alcoholic fatty liver disease, the increased 
risk in thrombosis was not linked to aberrant ADAMTS13 
levels or hyperactive haemostasis (80).
Conclusion
As summarised above, selected members of ADAM and 
ADAMTS proteinase families display altered expression in 
different liver pathologies, and a mechanistical role in the 
pathology has been shown for some members. However, we 
are still far from fully understanding the complex nature of 
ADAM and ADAMTS proteinases and their impact on liver 
physiology and pathology. Substrate analysis on a proteom-
ics level will help to unveil how ADAM and ADAMTS pro-
teinases regulate liver biology.
Further studies will also show if  ADAM and ADAMTS 
expression and activity can be harnessed for diagnostic or 
therapeutic purposes. ADAMTS13 activity is already rou-
tinely assessed for the diagnosis of thrombotic thrombocy-
topenia purpura. Extended studies will determine the utility 
and benefit of ADAMTS13 activity measurement in the clin-
ical management of acute and chronic liver disease. Albeit 
overexpression of some ADAM proteases has been shown in 
liver pathologies, more extended human studies, and exper-
imental in vivo studies using targeted deletion, in particular 
hepatic cell types of the liver, are warranted to better under-
stand the role of ADAM proteases in liver pathologies and 
targeted diagnosis and therapeutics.
There have been numerous research activities in the past 
to develop small molecule inhibitors for ADAM17 to treat 
chronic inflammatory diseases such as rheumatoid arthritis. 
However, the first chemical entities displayed musculoskeletal 
and hepatic toxicities and therefore did not proceed beyond 
phase I/II clinical trials (81). A recently developed dual-spe-
cific ADAM10/17 inhibitor, INCB7839 (25), is a promising 
candidate that is currently in a clinical trial phase I/II study 
(NCT02142451) for the treatment of diffuse large B-cell 
non-hodgkin lymphoma. In addition, very recently, the re-
combinant pro-domain of ADAM17 has been developed as 
a specific ADAM17 inhibitor in vitro and in vivo and might 
represent a novel strategy to specifically inhibit ADAM 
and ADAMTS proteinases (16). In summary, the world of 
ADAM and ADAMTS proteinases remains a rich but largely 
underexplored sea of therapeutic opportunities.
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